Prelude Therapeutics Incorporated
PRLD
$5.55
$0.193.55%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 22.42M | 16.72M | 12.14M | 10.50M | 7.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.42M | 16.72M | 12.14M | 10.50M | 7.00M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 22.42M | 16.72M | 12.14M | 10.50M | 7.00M |
| SG&A Expenses | 20.29M | 21.67M | 22.31M | 23.62M | 26.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 88.52M | 99.56M | 115.41M | 131.55M | 142.01M |
| Operating Income | -66.10M | -82.84M | -103.27M | -121.05M | -135.01M |
| Income Before Tax | -60.49M | -77.80M | -99.50M | -111.77M | -124.32M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -60.49 | -77.80 | -99.50 | -111.77 | -124.32 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -60.49M | -77.80M | -99.50M | -111.77M | -124.32M |
| EBIT | -66.10M | -82.84M | -103.27M | -121.05M | -135.01M |
| EBITDA | -64.51M | -81.17M | -101.56M | -119.27M | -133.25M |
| EPS Basic | -0.73 | -1.00 | -1.30 | -1.47 | -1.64 |
| Normalized Basic EPS | -0.45 | -0.62 | -0.80 | -0.92 | -1.02 |
| EPS Diluted | -0.86 | -1.13 | -1.30 | -1.47 | -1.64 |
| Normalized Diluted EPS | -0.45 | -0.62 | -0.80 | -0.92 | -1.02 |
| Average Basic Shares Outstanding | 336.75M | 314.36M | 307.82M | 303.98M | 303.70M |
| Average Diluted Shares Outstanding | 336.75M | 314.36M | 307.82M | 303.98M | 303.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |